Clearside Biomedical Inc (CLSD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Clearside Biomedical Inc (CLSD) has a cash flow conversion efficiency ratio of 0.102x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.48 Million) by net assets ($-53.95 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CLSD net asset quality score to measure how much of total assets are equity-financed.
Clearside Biomedical Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Clearside Biomedical Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Clearside Biomedical Inc to evaluate the quality of earnings relative to operating cash generation.
Clearside Biomedical Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Clearside Biomedical Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Candela Invest SA
BR:CAND
|
0.050x |
|
Braille Energy Systems Inc
V:BES
|
-0.049x |
|
Lucapa Diamond Co Ltd
F:NHY
|
-0.007x |
|
Key Alliance Group Bhd
KLSE:0036
|
1.245x |
|
Kontrol Energy Corp
NEO:KNR
|
-0.005x |
|
ZIMI Ltd
AU:ZMM
|
-0.423x |
|
Miramar Resources Ltd
AU:M2R
|
-0.007x |
|
Edible Garden AG Inc
NASDAQ:EDBL
|
0.028x |
Annual Cash Flow Conversion Efficiency for Clearside Biomedical Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Clearside Biomedical Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Clearside Biomedical Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-38.85 Million | $-24.70 Million | 0.636x | -44.23% |
| 2023-12-31 | $-15.91 Million | $-18.14 Million | 1.140x | +190.45% |
| 2022-12-31 | $10.61 Million | $-13.37 Million | -1.260x | -345.81% |
| 2021-12-31 | $37.98 Million | $-10.73 Million | -0.283x | +81.12% |
| 2020-12-31 | $8.76 Million | $-13.12 Million | -1.497x | +38.29% |
| 2019-12-31 | $11.16 Million | $-27.07 Million | -2.426x | +27.65% |
| 2018-12-31 | $23.62 Million | $-79.20 Million | -3.353x | -40.57% |
| 2017-12-31 | $21.41 Million | $-51.08 Million | -2.385x | -652.72% |
| 2016-12-31 | $71.66 Million | $-22.71 Million | -0.317x | -183.57% |
| 2015-12-31 | $-36.66 Million | $-13.90 Million | 0.379x | -20.14% |
| 2014-12-31 | $-19.21 Million | $-9.12 Million | 0.475x | -25.44% |
| 2013-12-31 | $-10.74 Million | $-6.84 Million | 0.637x | +104.79% |
| 2012-12-31 | $239.00K | $-3.18 Million | -13.289x | -- |
About Clearside Biomedical Inc
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, whic… Read more